树突状细胞-细胞因子诱导的细胞免疫联合TC化疗治疗ⅡB-ⅣA期宫颈癌患者的疗效观察  

Therapeutic Effect of Dendritic Cell-cytokine-induced Cellular Immunity Combined with TC Chemotherapy on Patients with Stage ⅡB-ⅣA Cervical Cancer

作　　者：焦敏[1] 郭卉[1] 王淑红[1] 孙红[1] 秦天洁[1] JIAO Min;GUO Hui;WANG Shu-hong(Department of Oncology,the First Hospital of Xi'an Jiao Tong University,Xi'an,Shaanxi,710061)

机构地区：[1]西安交通大学第一附属医院肿瘤内科,陕西西安710061

出　　处：《医学临床研究》2019年第10期1904-1907,共4页Journal of Clinical Research

摘　　要：【目的】探讨树突状细胞-细胞因子诱导的杀伤(DC-CIK)细胞免疫联合紫杉醇+卡铂(TC)化疗治疗ⅡB-ⅣA期宫颈癌患者的疗效观察。【方法】选取2016年9月至2018年8月在本院诊治的72例ⅡB-ⅣA期宫颈癌患者,按照随机数表法分为观察组和对照组,每组36例。对照组给予TC化疗,观察组在对照组基础上加用DC-CIK细胞免疫治疗,比较两组治疗4个周期后客观缓解率、疾病控制率、Th1/Th2分泌因子[白介素-2(IL-2)、IL-10]水平、PI3K/Akt信号转导通路指标[磷脂酰肌醇-3-激酶(PI3K)、蛋白激酶B(Akt)、氨基末端激酶1(JNK1)]、骨桥蛋白(OPN)、内皮糖蛋白(CD105)水平及世界卫生组织生存质量调查表简表评分(WHOQOL-BREF)。【结果】治疗4个周期后,观察组客观缓解率、疾病控制率分别为63.89%、91.67%,均显著高于对照组的36.11%、66.67%;IL-2高于对照组,IL-10低于对照组;PI3K、Akt、JNK1、JNK2、JAK2、OPN、CD105水平低于对照组,其差异均有统计学意义(P<0.05);观察组治疗4个周期后WHOQOL-BREF评分显著高于对照组(P<0.05)。【结论】DC-CIK细胞免疫联合TC化疗治疗ⅡB-ⅣA期宫颈癌,抑制肿瘤增殖、浸润、转移,改善患者免疫功能,提高患者生活质量,疗效显著,其机制可能与抑制PI3K/Akt信号转导通路表达有关。【Objective】To investigate the efficacy of dendritic cell-cytokine-induced killer(DC-CIK)cell immunization combined with taxol plus carboplatin(TC)chemotherapy in patients with stage ⅡB-ⅣA cervical cancer.【Methods】From September 2016 to August 2018,72 patients with stage ⅡB-ⅣA cervical cancer in our hospital were selected and divided into observation group and control group with 36 cases in each group according to the random number table method.The control group was treated with TC chemotherapy,the observation group was treated with DC-CIK cell immunotherapy on the basis of the control group.Objective remission rate,disease control rate,Th1/Th2 secretion factor(IL-2,IL-10),PI3K/Akt signal transduction pathway index[phosphatidylinositol-3-kinase(PI3K),protein kinase B(Akt),amino terminal kinase 1(JNK1)],osteopontin(OPN),endothelial glycoprotein(CD105)and the World Health Organization Quality of Life questionnaire summary score(WHOQOL-BREF)were compared between the two groups.【Results】After 4 cycles of treatment,the objective remission rate and disease control rate of the observation group were 63.89%and 91.67%,respectively,which were significantly higher than 36.11%and 66.67%of the control group;IL-2 was higher than the control group,and IL-10 was lower than the control group;the levels of PI3K,Akt,JNK1,jnk2,JAK2,OPN and CD105 were lower than the control group,and the differences were statistically significant(P<0.05);the WHOQOL-BREF score of the observation group after 4 cycles of treatment was significant.It was higher than that of the control group(P<0.05).【Conclusion】DC-CIK cell immunity combined with TC chemotherapy in the treatment of ⅡB-ⅣA stage cervical cancer can inhibit tumor proliferation,invasion and metastasis,improve the immune function of patients,improve the quality of life of patients,and the effect is significant.The mechanism may be related to the inhibition of PI3K/Akt signal transduction pathway expression.

关 键 词：宫颈肿瘤/治疗 药物疗法 免疫疗法 

分 类 号：R711.74[医药卫生—妇产科学]